EUVIMEDEUVIMED entdecken
Multizentrische Studie

Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life

Vincenzo Marotta iD, Domenico Rocco, Anna Crocco, Maria Grazia Deiana, Ruggero Martinelli, Francesca Di Gennaro, Mariafelicia Valeriani, Luca Valvano, Alessia Caleo, Luciano Pezzullo, Antongiulio Faggiano, Mario Vitale und 1 weitere

The Journal of Clinical Endocrinology & Metabolism · 16.09.2024 · 109 (10) · 2541-2552

DOI: 10.1210/clinem/dgae181 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 19.03.2024. Verfasst von Vincenzo Marotta und 12 weiteren Autor:innen. Beteiligte Einrichtung: UOC Clinica Endocrinologica e Diabetologica, AOU San Giovanni di Dio e Ruggi d'Aragona, 84131, Salerno, Italy. Hauptthemen laut MEDLINE: Antineoplastic Agents, Iodine Radioisotopes, Phenylurea Compounds, Quinolines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Lenvatinib is approved for the treatment of radioiodine-refractory differentiated thyroid cancer (RR-DTC). The definition of predictive factors of survival is incomplete.

Objective

To identify pre- and posttreatment survival predictors in a real-life cohort of RR-DTC treated with lenvatinib.

Design

Multicenter, retrospective, cohort study.

Setting

3 Italian thyroid cancer referral centers.

Participants

55 RR-DTC treated with lenvatinib. Main Outcome Measures Progression-free survival (PFS) and overall survival (OS).

Results

Lenvatinib was the first-line kinase-inhibitor in 96.4% of subjects. Median follow-up was 48 months. Median PFS and OS were 26 [95% confidence interval (CI) 19.06-32.93] and 70 months (95% CI 36-111.99), respectively. Pretreatment setting: Eastern Cooperative Oncology Group (ECOG) performance status was independently related to PFS [P < .001; hazard ratio (HR) 18.82; 95% CI 3.65-97.08: score 0-1 as reference] and OS (P = .001; HR 6.20; 95% CI 2.11-18.20; score 0-1 as reference); radioactive iodine (RAI) avidity was independently related to PFS (P = .047; HR 3.74; 95% CI 1.01-13.76; avid disease as reference). Patients with good ECOG status (0-1) and RAI-avid disease obtained objective response in 100% of cases and achieved a median PFS of 45 months without any death upon a median follow-up of 81 months. Posttreatment setting: the best radiological response independently predicted PFS (P = .001; HR 4.6; 95% CI 1.89-11.18; partial/complete response as reference) and OS (P = .013; HR 2.94; 95% CI 1.25-6.89; partial/complete response as reference).

Conclusion

RR-DTC with good performance status and RAI-avid disease obtains the highest clinical benefit from lenvatinib. After treatment initiation, objective response was the only independent survival predictor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsIodine RadioisotopesPhenylurea CompoundsQuinolinesThyroid NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedFollow-Up StudiesPrognosisProgression-Free SurvivalProtein Kinase InhibitorsRetrospective Studies

Stichwörter der Autor:innen

envatinibkinase inhibitorsradioiodine-refractorythyroid cancerthyroid neoplasmsthyroid nodules

Substanzen

Antineoplastic AgentsIodine RadioisotopeslenvatinibPhenylurea CompoundsProtein Kinase InhibitorsQuinolines

Autor:innen und Institutionen

  • UOC Clinica Endocrinologica e Diabetologica, AOU San Giovanni di Dio e Ruggi d'Aragona, 84131, Salerno, Italy.
  • Dipartimento di Medicina, Chirurgia e Odontoiatria, Università di Salerno, 84084, Salerno, Italy.
  • Struttura Complessa Chirurgia Oncologica Della Tiroide, Istituto Nazionale Tumori-Irccs-Fondazione G. Pascale, 80131, Napoli, Italy.
  • Endocrinology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, ENETS Center of Excellence, Sapienza University of Rome, 00198, Rome, Italy.
  • Struttura Complessa Medicina Nucleare e Terapia Radiometabolica-UOS Terapia Metabolica Sperimentale, Istituto Nazionale Tumori-Irccs-Fondazione G. Pascale, 80131, Napoli, Italy.
  • UOC Chirurgia Generale, AOU San Giovanni di Dio e Ruggi d'Aragona, 84131, Salerno, Italy.

ORCID-Profile: Vincenzo Marotta

Zitieren

APA

Marotta, V., Rocco, D., Crocco, A., Deiana, M. G., Martinelli, R., Di Gennaro, F., Valeriani, M., Valvano, L., Caleo, A., Pezzullo, L., Faggiano, A., Vitale, M., & Monti, S. (2024). Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life. The Journal of Clinical Endocrinology & Metabolism, 109(10), 2541-2552. https://doi.org/10.1210/clinem/dgae181

Vancouver

Marotta V, Rocco D, Crocco A, Deiana MG, Martinelli R, Di Gennaro F, et al. Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life. The Journal of Clinical Endocrinology & Metabolism. 2024;109(10):2541-2552. doi:10.1210/clinem/dgae181

BibTeX
@article{Marotta2024,
  author = {Marotta, Vincenzo and Rocco, Domenico and Crocco, Anna and Deiana, Maria Grazia and Martinelli, Ruggero and Di Gennaro, Francesca and Valeriani, Mariafelicia and Valvano, Luca and Caleo, Alessia and Pezzullo, Luciano and Faggiano, Antongiulio and Vitale, Mario and Monti, Salvatore},
  title = {Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  volume = {109},
  number = {10},
  pages = {2541--2552},
  doi = {10.1210/clinem/dgae181}
}
Kostenlos starten →